MedTrace Logo

Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion

NCT00336596 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2007-04-27

No results posted yet for this study

Summary

The purpose of the present, randomized, controlled multicenter phase III trial is to investigate the safety and efficacy of continuous 1-hour insonation of occluded middle cerebral artery with 2 MHz TCCS in stroke patients treated with intravenous tissue plasminogen activator (t-PA) within 3 hours after symptom onset.

Conditions

Interventions

PROCEDURE

transcranial ultrasound in patients treated with iv t-PA

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Ralf W Baumgartner, MD · University Hospital of Zurich, Department of Neurology, Zurich, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2009-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00336596 on ClinicalTrials.gov